Revenues for the first half of 2026 and update on AB Science’s activities
09/10/2026 – AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
29/09/2026 – AB Science today announces a revision of its operating plan and financial calendar following a “for cause” sponsor Good Clinical Practice (GCP) inspection
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
17/08/2026 – AB Science today announces the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million
10/08/2026 – AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million subscribed by a limited number of investors
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development
08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer
AB Science announces the successful completion of a EUR 2.3 million private placement
01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the completion of Step 3, evaluating the combination of AB8939 + venetoclax in patients with acute myeloid leukemia
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06/2026 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)